Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Free Cash Flow of -$19.6 million for Q1 2026, up 7.12% year-over-year from -$18.3 million in Q1 2025, and up 5.99% quarter-over-quarter from -$20.8 million in Q4 2025.
Oculis Holding AG (OCS) Free Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.12% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$77.7 million (down 28.08% YoY), while the FY2025 annual figure was -$79.6 million, down 43.84% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$19.6 million, up from -$20.8 million in the prior quarter.
- The five-year high for Free Cash Flow was -$5.2 million in Q4 2022, with the low at -$21.1 million in Q1 2025.
- The 5-year median for Free Cash Flow is -$15.7 million (2024), against an average of -$15.1 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 210.52% in 2023, then climbed 24.53% in 2024.
- Oculis Holding AG's Free Cash Flow stood at -$5.2 million in 2022, then plunged by 210.52% to -$16.0 million in 2023, then gained by 24.53% to -$12.1 million in 2024, then slumped by 72.3% to -$20.8 million in 2025, then grew by 5.99% to -$19.6 million in 2026.
- Business Quant data shows OCS's Free Cash Flow at -$19.6 million in Q1 2026, -$20.8 million in Q4 2025, and -$16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -25.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.64 Mn |
| Jun 30, 2026 | -25.64 Mn |
| Mar 31, 2026 | -19.58 Mn |
| Mar 31, 2026 | -19.58 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Dec 31, 2025 | -20.82 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Sep 30, 2025 | -16.62 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Jun 30, 2025 | -20.67 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Mar 31, 2025 | -21.08 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Dec 31, 2024 | -12.09 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |